Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target
February 12, 2019 at 17:50 PM EST
Nonalcoholic steatohepatitis, or "fatty liver" disease, is believed to affect some 20 million people in the United States, and a dearth of FDA-approved treatments makes it a big target for drug developers.
